graft failure: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by dreye

graft failure Introduction (What it is)

graft failure means a transplanted eye tissue graft no longer works as intended.
It most often refers to a corneal transplant that becomes persistently cloudy or swollen.
Clinicians use the term to describe a loss of graft clarity, function, or structural integrity over time.
It is commonly discussed after keratoplasty (corneal transplantation) and other ocular surface grafting procedures.

Why graft failure used (Purpose / benefits)

Although graft failure is an unwanted outcome, the concept is clinically useful because it gives clinicians and patients a shared framework for describing why a graft is not meeting its goal and what that might imply for vision and eye health.

In ophthalmology, grafts are used to restore transparency, protect the eye, or replace diseased tissue. For example, corneal transplants can improve vision when a cornea is scarred or swollen, and patch grafts can reinforce weak areas of the eye wall after surgery or injury. When a graft fails, it can reverse these benefits, leading to reduced vision, discomfort, or surface instability.

Using the term graft failure helps to:

Distinguish a persistent graft problem from short-term post-operative healing changes.
Separate different mechanisms (immune rejection, infection, pressure-related damage, recurrence of the original disease, surgical/technical factors).
Guide follow-up intensity and additional testing (for example, checking corneal thickness, intraocular pressure, or signs of inflammation).
Support clear communication in medical records and in research comparing outcomes across techniques and materials.
Frame decision-making about observation, medical treatment, or repeat surgery (often called regrafting), noting that specifics vary by clinician and case.

Indications (When ophthalmologists or optometrists use it)

Clinicians may raise concern for graft failure in situations such as:

Persistent corneal clouding or swelling after a corneal transplant that does not clear as expected.
Worsening vision attributable to loss of graft transparency rather than glasses/contact lens changes.
Clinical signs suggesting the corneal endothelium (the inner cell layer) is not functioning adequately.
Repeated or severe episodes of graft rejection with incomplete recovery of clarity.
Progressive surface breakdown, thinning, or “melt” of grafted tissue on the ocular surface.
Structural complications involving a patch graft (for example, thinning or exposure over a tube shunt or scleral repair site).
Recurrence of the original disease in the graft (for example, certain corneal dystrophies or scarring conditions).
Ocular comorbidities (such as uncontrolled inflammation or glaucoma) that are affecting graft performance.

Contraindications / when it’s NOT ideal

Because graft failure is a diagnosis/outcome rather than a treatment, “contraindications” usually refer to situations where labeling a problem as graft failure may be premature or where a grafting approach may be less suitable due to higher failure risk.

Situations where another explanation or approach may be considered include:

Early post-operative haze or swelling that may still be within the normal healing window (timelines vary by procedure and individual factors).
Vision loss primarily from non-graft causes, such as cataract, retinal disease, optic nerve disease, or irregular astigmatism despite a clear graft.
Dry eye disease, blepharitis, or exposure problems causing surface blur that mimics graft-related clouding.
Infection, persistent epithelial defects, or toxic surface reactions where the immediate issue is not “failure” of the graft tissue itself.
Eyes with severe ocular surface disease, uncontrolled inflammation, or severe eyelid malposition where standard grafting may have a higher risk of breakdown or melt.
Significant, poorly controlled glaucoma or other conditions that can damage corneal endothelial cells and shorten graft longevity.
Situations where alternative reconstructive strategies may be preferred (for example, different graft material, staged procedures, or specialized implants), noting that selection varies by clinician and case.

How it works (Mechanism / physiology)

graft failure is best understood by focusing on what a graft is supposed to do and what biological system is required to keep it working.

Mechanism and principle (high level)

In a corneal transplant, the goal is usually to restore a smooth, transparent window at the front of the eye so light can pass clearly to the retina.
The cornea stays clear partly because of the corneal endothelium, a thin inner cell layer that pumps fluid out of the cornea. If endothelial cells are damaged or lost beyond a functional threshold, the cornea can become swollen (edematous) and cloudy.
In ocular surface grafts (such as conjunctival or amniotic membrane grafting) or patch grafts (such as scleral patch grafts), success depends more on tissue integration, surface healing, blood supply, inflammation control, and mechanical stability.

Relevant anatomy and tissues

Cornea: epithelium (outer), stroma (middle), endothelium (inner).
Anterior chamber: the fluid-filled space behind the cornea.
Ocular surface: cornea, conjunctiva, eyelids, tear film.
Sclera (white of the eye): may receive patch grafts for reinforcement.

Onset, duration, and reversibility

“Onset” and “duration” vary widely because graft failure can be early (soon after surgery) or late (months to years later).
Some causes are potentially partly reversible if addressed promptly (for example, certain rejection episodes may improve), while other causes represent more permanent tissue dysfunction (for example, chronic endothelial failure or severe scarring).
Because graft failure is an outcome rather than a therapy, “duration” is better thought of as time to failure and time course of decline, both of which vary by clinician and case and by graft type.

graft failure Procedure overview (How it’s applied)

graft failure is not a procedure. It is a clinical term used when a transplanted tissue is not providing the intended clarity, coverage, or structural support.

A general clinical workflow when graft failure is suspected often includes:

Evaluation / exam – Review of symptoms (blurred vision, glare, foreign-body sensation, redness, light sensitivity) and timing. – Visual acuity testing and refraction (to check whether optics explain the change). – Slit-lamp examination to assess clarity, swelling, sutures, surface health, and signs of inflammation. – Intraocular pressure measurement, because pressure changes can influence corneal health.
Preparation – Clarify the graft type (full-thickness vs partial-thickness; endothelial vs stromal; surface graft vs patch graft). – Review past episodes of rejection, infections, surface breakdown, and prior surgeries.
Intervention / testing (as needed) – Imaging or measurements that may include corneal thickness assessment and evaluation of graft-host interface (choice varies by clinic and equipment). – Assessment for infection or epithelial defects if surface compromise is present. – Differentiation between immune rejection and non-immune causes based on exam findings and clinical course.
Immediate checks – Documentation of graft clarity, edema pattern, epithelial integrity, and inflammation level. – Determination of urgency (for example, severe inflammation, suspected infection, or rapid decline typically prompts closer follow-up).
Follow-up – Monitoring for stability or progression. – Discussion of broad management pathways, which may include medical therapy, procedural interventions, or consideration of repeat surgery depending on cause and severity (details vary by clinician and case).

Types / variations

graft failure can be categorized in several clinically meaningful ways.

By timing

Primary graft failure: the graft never achieves the expected function after surgery (often discussed with endothelial keratoplasty and full-thickness transplants). Causes can include tissue quality factors, surgical handling, or immediate post-operative complications; exact contributors vary by case.
Secondary (late) graft failure: the graft initially works but declines over time due to chronic cell loss, rejection, pressure-related damage, recurrence of disease, infection, or other stressors.

By mechanism

Immune-mediated failure (rejection-related): the immune system targets the graft. Rejection episodes may be reversible to varying degrees, but repeated or severe episodes can lead to permanent dysfunction.
Non-immune endothelial failure: gradual loss of endothelial cells leading to swelling and clouding without classic rejection findings.
Infectious complications leading to failure: infection can scar, damage tissue, or trigger secondary inflammation.
Surface breakdown / melt: thinning or tissue loss on the ocular surface that compromises graft integrity (more relevant to surface grafts and patch grafts, but can affect corneal grafts in severe surface disease).
Mechanical/structural problems: wound issues, suture-related complications, interface problems in lamellar grafts, or trauma.

By graft procedure type (cornea)

Penetrating keratoplasty (PK): full-thickness corneal transplant; failure often relates to endothelial dysfunction, rejection, astigmatism-related visual limitations (with a clear graft), or wound-related issues.
Endothelial keratoplasty (DSEK/DSAEK/DMEK): replacement of the endothelial layer (and varying amounts of adjacent tissue); failure is often discussed in terms of endothelial cell function and graft attachment/clarity.
Deep anterior lamellar keratoplasty (DALK): front corneal layers are replaced while preserving the patient’s endothelium; “failure” may relate more to scarring, interface haze, or surface issues than endothelial pump failure.

By tissue/site (beyond cornea)

Amniotic membrane or conjunctival graft failure: insufficient healing, recurrent inflammation, or tissue breakdown.
Scleral or corneal patch graft failure: thinning, exposure, or breakdown over implanted devices or repair sites.

Pros and cons

Pros:

Provides a clear label for a complex set of post-transplant problems.
Encourages systematic evaluation of common causes (immune, pressure-related, infectious, surface-related, mechanical).
Helps clinicians communicate prognosis and follow-up needs in a structured way.
Supports comparison of outcomes across graft types and surgical techniques.
Can guide timely recognition of potentially treatable contributors (for example, inflammation or ocular surface disease).
Helps separate graft tissue problems from unrelated causes of vision loss.

Cons:

Can sound definitive when the underlying issue may still be evolving or partially reversible.
May be used inconsistently across settings (definitions can vary by clinician, study criteria, and graft type).
Does not specify the cause; additional evaluation is required to distinguish mechanisms.
Can be confusing for patients when vision is poor despite a “clear graft” (optical issues may be the limiting factor instead).
May overlap with other terms such as “rejection,” “decompensation,” or “graft melt,” depending on the clinical context.
Emotional impact can be significant because it is often associated with the possibility of repeat surgery.

Aftercare & longevity

Outcomes after eye grafting—and the risk of graft failure—are influenced by multiple interacting factors. Longevity is not a fixed number and can differ substantially between individuals and between graft types.

Key influences often include:

Underlying diagnosis: Some corneal diseases have higher recurrence risk in transplanted tissue, while others primarily affect the endothelium.
Ocular surface health: Tear film instability, eyelid inflammation, exposure, and chronic irritation can compromise healing and transparency.
Inflammation and immune activity: Eyes with prior inflammation, vascularization (new blood vessels), or autoimmune disease may face higher immune-related risk.
Intraocular pressure (IOP) and glaucoma: Elevated IOP and glaucoma surgeries can stress the corneal endothelium and affect graft survival.
Infections: Past or current infections can increase scarring risk and complicate healing.
Surgical history: Multiple prior surgeries can increase complexity and affect tissue health.
Material and tissue factors: Donor tissue handling and characteristics, and device/material choice for patch grafts, can matter; specifics vary by material and manufacturer.
Follow-up consistency: Regular monitoring supports early detection of changes in clarity, pressure, and surface integrity, but exact schedules vary by clinician and case.

In practical terms, “aftercare” is often less about a single action and more about ongoing surveillance for clarity, comfort, surface stability, and pressure control.

Alternatives / comparisons

Because graft failure refers to a problem rather than a single treatment, “alternatives” depend on the underlying cause, severity, and visual needs. Common comparison pathways include:

Observation / monitoring
When changes are mild, stable, or potentially part of normal healing, clinicians may monitor for progression while investigating contributing factors.
This differs from confirmed graft failure, where the graft is no longer meeting functional goals.
Medication-focused management vs procedural management
If inflammation, dryness, or rejection-like findings are suspected, medical therapies may be used to reduce inflammation and support the ocular surface (specific regimens vary by clinician and case).
If structural problems, persistent edema, or significant scarring dominate, procedural options may be considered.
Optical rehabilitation instead of immediate repeat surgery
With a clear but irregular graft, vision may be limited by astigmatism or irregular corneal shape. In such cases, glasses or contact lenses (including rigid or scleral lenses) may improve vision without additional surgery, depending on suitability.
Repeat graft (regrafting) vs alternative surgical approaches
If the endothelial layer fails, an endothelial keratoplasty may be considered in some settings rather than repeating a full-thickness transplant, depending on anatomy and prior surgery.
In complex, high-risk eyes, specialized options such as a keratoprosthesis (artificial cornea) may be discussed by corneal specialists; candidacy varies widely.
Low-vision support
When vision cannot be fully restored by improving the cornea alone (for example, if retinal or optic nerve disease is also present), low-vision aids and rehabilitation can be an important parallel pathway.

graft failure Common questions (FAQ)

Q: Does graft failure mean the transplant was “rejected”?
Not always. Rejection is an immune response against the graft and is one possible cause. graft failure can also occur from non-immune endothelial decline, pressure-related damage, infection, surface breakdown, or mechanical factors.

Q: What are common symptoms people notice with graft failure?
Many people notice blurrier vision, increased glare, or a “foggy” view if the cornea becomes swollen or cloudy. Some may also notice redness, light sensitivity, or discomfort, especially if inflammation or surface problems are involved. Symptoms vary with the graft type and underlying cause.

Q: Is graft failure painful?
It can be painless if the main issue is internal corneal swelling. Pain or significant irritation is more likely when the ocular surface is involved, such as with an epithelial defect, severe dryness, infection, or tissue melt. The symptom pattern depends on the mechanism.

Q: How do clinicians confirm graft failure?
Confirmation is typically based on eye examination findings, changes in corneal clarity, and how the graft performs over time. Clinicians may also use measurements and imaging to assess corneal thickness, interface quality, and related factors. The exact tests vary by clinic and case.

Q: How long does a corneal graft last before graft failure happens?
There is no single timeline. Some grafts remain clear for many years, while others may fail earlier due to rejection, glaucoma, ocular surface disease, infection, or other stresses. Longevity varies by clinician and case and by graft type.

Q: Is graft failure preventable?
Risk can sometimes be reduced by addressing contributing factors like inflammation, ocular surface disease, and intraocular pressure, but prevention is not absolute. Some risks relate to the eye’s underlying condition and immune environment. Outcomes vary between individuals even with careful care.

Q: What happens if graft failure is diagnosed?
The next steps usually focus on identifying the cause and determining whether the problem is reversible, stabilizable, or likely permanent. Management may range from closer monitoring and medical therapy to procedural options, including the possibility of repeat surgery. The approach depends on the graft type and clinical findings.

Q: Can people drive or use screens if they have graft failure?
Many people can still use screens, though blur and glare may be limiting. Driving depends on functional vision and local legal vision requirements, which are not the same for everyone. Clinicians typically assess vision and safety concerns in context.

Q: How much does evaluation or treatment for graft failure cost?
Costs vary widely by region, insurance coverage, clinic setting, and what testing or procedures are needed. Office visits and diagnostic testing differ from surgical costs, and repeat surgery typically changes the overall expense. A clinic’s billing team can often explain general categories of charges.

Q: Is graft failure the same as “a cloudy cornea”?
A cloudy cornea is a description, not a diagnosis. Corneal clouding after transplantation can result from edema due to endothelial dysfunction (a common pathway in graft failure), but it can also come from scarring, infection, or surface problems. The distinction matters because the management and prognosis differ.